<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The macro- and microvascular burden of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is well established </plain></SENT>
<SENT sid="1" pm="."><plain>A number of recent single risk factor intervention trials targeting <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, procoagulation, microalbumuria, and existing <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorders</z:e> have, however, shown major beneficial effects on long-term outcome </plain></SENT>
<SENT sid="2" pm="."><plain>The results from these studies are anticipated to change the future management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and most of the updated national guidelines for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> recommend a multipronged approach driven by ambitious treatment targets </plain></SENT>
<SENT sid="3" pm="."><plain>The outcome of this intensive integrated therapy has, however, only been investigated in a few studies of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>One of these trials, the Steno-2 Study, showed that intensive intervention for an average of 7.8 years cuts cardiovascular events as well as <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, and <z:e sem="disease" ids="C0259749" disease_type="Disease or Syndrome" abbrv="">autonomic neuropathy</z:e> by about half when compared with a conventional multifactorial treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The challenge for now is to ensure that the trial experiences are widely adopted in daily clinical practice </plain></SENT>
</text></document>